Strategic Partnering and Analytics

Home/Strategic Partnering and Analytics
Strategic Partnering and Analytics 2018-08-13T15:13:21+00:00

LifeSci Strategic Partnering

Who We Are

LifeSci Strategic Partnering provides business development and strategic consulting to life science companies across all therapeutic areas and development stages. Our team has a proven track record with a global client base in the diverse fields of oncology, inflammation, cardiometabolic diseases, rare diseases, neurology, infectious diseases, dermatology and others.

What We Do

We facilitate partnerships and strategic transactions including in- and out-licensing agreements, M&A collaborations and R&D collaborations. LifeSci Strategic Partnering focuses on securing non-dilutive capital in the forms of upfront payments, development, regulatory and commercial milestone payments, royalties and full or partial R&D funding.

LifeSci Analytics

Who We Are

LifeSci Analytics delivers market and financial analytics that empower both business and corporate development activities. Our team has substantial experience across therapeutic areas, with specific expertise in asset valuations, competitive landscape and commercial analyses, strategic planning and indication selection assessments.

What We Do

We provide primary and secondary market research and financial analyses to assist companies in understanding and effectively articulating asset value propositions to both investors and strategic partners. Our analyses guide companies’ internal development and capital allocation decisions. By leveraging our vast network of key opinion leaders, high volume prescribers and third-party payers, our market research ascertains current market dynamics, identifies areas of unmet medical need and assesses the commercial potential of programs.

The Team

The LifeSci Strategic Partnering and Analytics team has executed 80+ mandates that have supported strategic transactions, financing activities, internal capital rationing and development decisions for companies spanning all therapeutic areas and development stages. The team has advised on 20+ transactions with a total deal value exceeding $2.3 billion. Our extensive global network of contacts comprised of C-level executives, business and corporate development executives, and R&D teams allows our team to complete transactions expeditiously and under the most advantageous terms for our clients.

Managing Director

amc
Michael Cozart is an experienced strategic consultant who has advised both publicly-traded as well as privately held life sciences companies across the globe. Michael has expertise across all therapeutic areas with specific expertise in oncology, cardiometabolic diseases, dermatology, immunology, rare diseases, neurology, and medical devices. Prior to joining LifeSci Advisors, Michael was a Vice President at Destum Partners, a boutique life sciences consulting firm, where he supported transactions totaling over $1.75 billion and executed 40+ strategic consulting mandates. Michael received a B.A. in Economics and English from the University of North Carolina at Chapel Hill.

Managing Director

amc
Jason Laffin has nearly a decade of experience in the healthcare industry supporting strategic transactions and executing market and financial analytics engagements. Jason’s global clientele has included small- to mid-sized publicly traded and privately held companies developing assets in various therapeutic areas, including oncology, infectious diseases, cardiometabolic diseases, neurology, rare diseases, medical devices, and animal health. Prior to joining LifeSci Advisors, Jason was a Vice President at Destum Partners, a boutique life sciences consulting firm, where he supported transactions totaling over $1.6 billion and executed 40+ strategic consulting mandates. Jason received an M.B.A. from the McColl School of Business at Queens University of Charlotte and a B.S. in Physics and Math from Siena College.